Literature DB >> 35308677

When Bullous Pemphigoid Is Not Bullous Pemphigoid: The Importance of Going Beyond Direct Immunofluorescence.

Christina R Hopkins1, Vicky Ren1, Raminder Grover2, Clay Cockerell3, Sylvia Hsu4.   

Abstract

Bullous pemphigoid (BP) is the most common autoimmune bullous disease, but rarer forms of pemphigoid may appear identical to BP on routine histopathology and direct immunofluorescence (DIF). Here, we present the case of a 60-year-old man, who was initially thought to have BP, with supportive findings on routine histopathology and DIF. However, prominent oral involvement and cutaneous lesions refractory to conventional treatment suggested an alternate diagnosis. Further workup was performed, including indirect immunofluorescence (IIF) on salt-split skin, which showed binding of antibodies to the dermal floor rather than to the blister roof, and enzyme-linked immunosorbent assay for pemphigus and pemphigoid antibodies. With these additional tests, we concluded that the patient does not have BP but rather anti-p200 pemphigoid, anti-p105 pemphigoid, or a yet undiscovered form of pemphigoid. We reached a presumptive diagnosis of anti-p200 pemphigoid, as it is the most common pemphigoid with serum antibodies to the dermal floor of human salt-split skin by IIF. This case demonstrates that suspicion for other autoimmune bullous diseases in cases of treatment-refractory and clinically aberrant BP is essential. A limited workup may lead to a missed diagnosis and ultimately less efficient disease management.
Copyright © 2022, Hopkins et al.

Entities:  

Keywords:  anti-p105 pemphigoid; anti-p200 pemphigoid; autoimmune bullous disease; bullous pemphigoid; direct immunofluorescence; indirect immunofluorescence; laminin gamma-1; salt-split skin

Year:  2022        PMID: 35308677      PMCID: PMC8925621          DOI: 10.7759/cureus.22201

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  9 in total

1.  Laboratory Diagnosis and Clinical Profile of Anti-p200 Pemphigoid.

Authors:  Joost M Meijer; Gilles F H Diercks; Enno Schmidt; Hendri H Pas; Marcel F Jonkman
Journal:  JAMA Dermatol       Date:  2016-08-01       Impact factor: 10.282

2.  Anti-p200 pemphigoid is the most common pemphigoid disease with serum antibodies against the dermal side by indirect immunofluorescence microscopy on human salt-split skin.

Authors:  Imke Lau; Stephanie Goletz; Maike M Holtsche; Detlef Zillikens; Kai Fechner; Enno Schmidt
Journal:  J Am Acad Dermatol       Date:  2019-04-03       Impact factor: 11.527

3.  Usefulness of a Simple Immunohistochemical Staining Technique to Differentiate Anti-p200 Pemphigoid From Other Autoimmune Blistering Diseases: A Report of 2 Cases.

Authors:  I García-Díez; M E Martínez-Escala; N Ishii; T Hashimoto; J M Mascaró Galy; R M Pujol; J E Herrero-González
Journal:  Actas Dermosifiliogr       Date:  2016-04-16

4.  U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases.

Authors:  R M Vodegel; M F Jonkman; H H Pas; M C J M de Jong
Journal:  Br J Dermatol       Date:  2004-07       Impact factor: 9.302

5.  A novel immune-mediated subepidermal bullous dermatosis characterized by IgG autoantibodies to a lower lamina lucida component.

Authors:  L S Chan; K D Cooper
Journal:  Arch Dermatol       Date:  1994-03

6.  Histopathology of anti-p200 pemphigoid.

Authors:  Christian Rose; Wolfgang Weyers; Natalja Denisjuk; Uwe Hillen; Detlef Zillikens; Iakov Shimanovich
Journal:  Am J Dermatopathol       Date:  2007-04       Impact factor: 1.533

Review 7.  Bullous pemphigoid.

Authors:  Denise Miyamoto; Claudia Giuli Santi; Valéria Aoki; Celina Wakisaka Maruta
Journal:  An Bras Dermatol       Date:  2019-05-09       Impact factor: 1.896

8.  Anti-p200 Pemphigoid: A Systematic Review.

Authors:  Khalaf Kridin; A Razzaque Ahmed
Journal:  Front Immunol       Date:  2019-10-22       Impact factor: 7.561

Review 9.  Diagnosis of Autoimmune Blistering Diseases.

Authors:  Mareike Witte; Detlef Zillikens; Enno Schmidt
Journal:  Front Med (Lausanne)       Date:  2018-11-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.